HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Henkel

This article was originally published in The Rose Sheet

Executive Summary

German company lowers FY 2004 organic growth forecast from 3%-4% to 2% due to "ongoing sluggish demand" in Europe and a "stagnant to downward trend of the markets and tougher competition as well as pricing activities" of the firm's competitors. Brand investment and cost reduction measures already have been instituted to improve Henkel's performance, company adds. Firm will report second quarter results Aug. 9...

You may also be interested in...



Will Switzerland’s Only EU Notified Body Survive Swixit Threat?

What will the fall-out of political tensions between the EU and Switzerland mean for notified bodies based in Switzerland, and for the future recognition of CE marks granted in one of the most important medtech markets in Europe?

QUOTED. 19 February 2020. Stephen Hahn.

The US FDA has abandoned all near-term plans to inspect Chinese manufacturing facilities in the wake of the coronavirus crisis. See what agency head Stephen Hahn said about it here.

DevaCurl Faces Multiple Class Actions As Latest Brand Linked To Hair Loss

The company maintains that its products are safe, but plaintiffs in proposed class actions allege it has knowingly put consumers at risk of hair loss and other injuries. DevaCurl’s troubles escalated quickly after a former brand ambassador went viral with a 31 January video urging consumers to stop using DevaCurl products and adopt safer alternatives.

UsernamePublicRestriction

Register

RS012281

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel